SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Petri M. Dermatologic lupus: Hopkins Lupus Cohort. Semin Cutan Med Surg 1998; 17: 21927.
  • 2
    Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort: LUpus in MInority populations, NAture vs. Nurture. Lupus 1999; 8: 197209.
  • 3
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 4
    Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 19559.
  • 5
    Soares M, Reis L, Papi JA, Cardoso CR. Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients. Lupus 2003; 12: 78894.
  • 6
    Vilar MJ, Bezerra EL, Sato EI. Skin is the most frequently damaged system in recent-onset systemic lupus erythematosus in a tropical region. Clin Rheumatol 2005; 24: 37780.
  • 7
    Guarize J, Appenzeller S, Costallat LT. Skin damage occurs early in systemic lupus erythematosus and independently of disease duration in Brazilian patients. Rheumatol Int 2007; 27: 4837.
  • 8
    Hale ED, Treharne GJ, Norton Y, Lyons AC, Douglas KM, Erb N, et al. ‘Concealing the evidence’: the importance of appearance concerns for patients with systemic lupus erythematosus. Lupus 2006; 15: 53240.
  • 9
    Gilbert P. The evolution of social attractiveness and its role in shame, humiliation, guilt and therapy. Br J Med Psychol 1997; 70: 11347.
  • 10
    Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490500.
  • 11
    Vila LM, Alarcon GS, McGwin G Jr, Friedman AW, Baethge BA, Bastian HM, et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43: 35863.
  • 12
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 13
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 14
    US Department of Commerce, Bureau of the Census. Current population reports: series P-23, no. 28 and series P-60, no. 68 and subsequent years. Washington (DC): Housing and Household Economic Statistics Division; 1995.
  • 15
    Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 15260.
  • 16
    Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 17
    Aarden LA, De Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975; 254: 50515.
  • 18
    Hamilton RG, Harley JB, Bias WB, Roebber M, Reichlin M, Hochberg MC, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus: correlation of HLA–DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988; 31: 496505.
  • 19
    Harris EN. Special report: the Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990; 94: 47684.
  • 20
    Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70: 78793.
  • 21
    Engle EW, Callahan LF, Pincus T, Hochberg MC. Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitudes Index. Arthritis Rheum 1990; 33: 2816.
  • 22
    Cohen S, Mermelstein R, Kamarck T, Hoberman HN. Measuring the functional components of social support. In: SarasonIG, SarasonBR, editors. Social support: theory, research and applications. Boston: Martinus Nijhoff; 1985. p. 7394.
  • 23
    Pilowsky I. Dimensions of illness behavior as measured by the Illness Behavior Questionnaire: a replication study. J Psychosom Res 1993; 37: 5362.
  • 24
    Schmoor C, Caputo A, Schumacher M. Evidence from nonrandomized studies: a case study on the estimation of causal effects. Am J Epidemiol 2008; 167: 11209.
  • 25
    Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59: 43747.
  • 26
    Pons-Estel GJ, Gonzalez LA, Zhang J, Vila LM, Reveille JD, Alarcon GS. Smoking is strong predictor of integument damage in patients with lupus: data from LUMINA multiethnic US cohort [abstract]. Lupus 2008; 17: 4823.
  • 27
    Cooper GS, Treadwell EL, St.Clair EW, Gilkeson GS, Dooley MA. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 9939.
  • 28
    Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797806.
  • 29
    Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 19559.
  • 30
    Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009; 48: 7735.
  • 31
    Mok CC, Ho CT, Wong RW, Lau CS. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 15139.
  • 32
    Zonana-Nacach A, Yanez P, Jimenez-Balderas FJ, Camargo-Coronel A. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 1998; 7: 11923.
  • 33
    Rivest C, Lew RA, Welsing PM, Sangha O, Wright EA, Roberts WN, et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol 2000; 27: 6804.
  • 34
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 1504.
  • 35
    Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus: prospective long-term study of an Israeli cohort. Lupus 2002; 11: 35661.
  • 36
    Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 147380.
  • 37
    Alarcon GS, McGwin G Jr, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 116872.
  • 38
    Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al, and the Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 805.
  • 39
    Wozniacka A, Lesiak A, Narbutt J, Kobos J, Pavel S, Sysa-Jedrzejowska A. Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 8994.
  • 40
    Sjolin-Forsberg G, Berne B, Eggelte TA, Karlsson-Parra A. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995; 75: 22831.
  • 41
    Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25: 17169.
  • 42
    Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006; 85: 2218.
  • 43
    Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 88994.
  • 44
    Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 3747.